|
Age, years
|
62 ± 17
|
|
Sex
|
Male (79%)
|
|
NYHA functional class III-IV
|
17 (21%)
|
|
(I 31; II 33; III 15; IV 2)
| |
|
Etiology
| |
|
IHD
|
22 (27%)
|
|
Non-IHD
|
59 (73%)
|
|
Valvular disease
|
4 (5%)
|
|
DCM
|
37 (46%)
|
|
HCM
|
5 (6%)
|
|
HHD
|
7 (9%)
|
|
Others
|
6 (7%)
|
|
Electrocardiogram
| |
|
Sinus rhythm
|
54 (67%)
|
|
Atrial fibrillation
|
19 (23%)
|
|
Pacing rhythm
|
8 (10%)
|
|
Medications
| |
|
Beta-blocker
|
62 (78%)
|
|
ACE-I/ARB
|
65 (80%)
|
|
Calcium channel blocker
|
16 (20%)
|
|
Diuretic
|
61 (75%)
|
|
Aldosterone antagonist
|
47 (58%)
|
|
Laboratory test
| |
|
BNP (pg/mL)
|
765 ± 870
|
|
Uric acid (mg/dL)
|
7.4 ± 2.6
|
|
Hemoglobin (g/dL)
|
14.0 ± 2.1
|
|
Total bilirubin (mg/dL)
|
1.1 ± 0.8
|
|
C-reactive protein (mg/dL)
|
1.5 ± 2.9
|
|
eGFR (mL/min/1.73 m2)
|
51 ± 20
|
|
Echocardiographic examination
| |
|
LAD (cm)
|
4.1 ± 0.8
|
|
IVSTd (cm)
|
1.0 ± 0.3
|
|
LVPWTd (cm)
|
1.1 ± 0.3
|
|
LVDd (cm)
|
6.1 ± 1.0
|
|
LVDs (cm)
|
5.4 ± 1.1
|
|
LVEF (%)
|
30 ± 8
|
|
RVFAC (%)
|
35 ± 14
|
|
TR-PG (mmHg)
|
25 ± 12
|
- Values are expressed as absolute numbers (%) or the mean ± SD.
-
NYHA New York Heart Association, IHD ischemic heart disease, DCM dilated cardiomyopathy, HCM hypertrophic cardiomyopathy, HHD hypertensive heart disease, Others include 2 sarcoidosis, 1 LV noncompaction, 1 restrictive cardiomyopathy and 2 unknown origin, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II type 1 receptor antagonist, BNP brain natriuretic peptide, eGFR estimated glomerular filtration rate, LAD left atrial dimension (diastole), IVSd intraventricular septal wall thickness (diastole), LVPWTd left ventricular posterior wall thickness (diastole), LVEF left ventricular ejection fraction, RVFAC right ventricular fractional area change, TR-PG tricuspid regurgitation-pressure gradient.
